02.02.17
Ionis Pharmaceuticals, Inc. has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. The companies have a broad strategic collaboration focused on leveraging antisense technology to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development.
"The recent FDA approval of SPINRAZA highlights the potential of our antisense technology to address neurological diseases with high unmet need," said B. Lynne Parshall, chief operating officer at Ionis. "This latest milestone is one more example of the success of our strategic collaboration with Biogen. Under this collaboration, we have advanced SPINRAZA to commercialization and another four drugs into development. We have also validated four more targets with drug candidates that we are advancing toward development. This work has generated a combined total of approximately $555 million to date. As we enter 2017, we expect to continue to make significant progress in growing our neurological disease pipeline."
"The recent FDA approval of SPINRAZA highlights the potential of our antisense technology to address neurological diseases with high unmet need," said B. Lynne Parshall, chief operating officer at Ionis. "This latest milestone is one more example of the success of our strategic collaboration with Biogen. Under this collaboration, we have advanced SPINRAZA to commercialization and another four drugs into development. We have also validated four more targets with drug candidates that we are advancing toward development. This work has generated a combined total of approximately $555 million to date. As we enter 2017, we expect to continue to make significant progress in growing our neurological disease pipeline."